Skip to main content

Table 9 Stage 3 or 4 sleep (%) in randomized controlled trials of APAP versus CPAP

From: Auto-titrating versus fixed continuous positive airway pressure for the treatment of obstructive sleep apnea: a systematic review with meta-analyses

Study

PMID

Baseline AHI (SD)

[eligibility]

Baseline ESS (SD)

Duration (design)

Interventions

Number analyzed

Baseline (SD)

Change

(final)

Net difference

or difference

95% CIa

P

Dropout (%)

Study quality

d'Ortho 2000 [32]

11035671

58 (6)

[≥10]

12.7 (5.3)

2 months

(XO)

APAP

25

44 min (36)

43

-9 min

nd

NS

0

B

    

CPAP

25

44 min (36)

52

     

Hussain 2004 [20]

15072173

47 (36)

[> 15]

11.1 (6.4)

1 month

(XO)

APAP

10

14 (25)

-4.0

-8

-18.32 to 2.32

nd

0

C

    

CPAP

10

14 (25)

4.0

     

Konermann 1998 [31]

9515848

38 (14)

[> 20]

nd

3 to 6 months

(PL)

APAP

25

13.2

(12.2)

14

7.8

1.8 to 13.7b

< 0.01

4

B

    

CPAP

23

11.4

(10.4)

6.2

     

Meurice 2007 [13]

17638595

55 (10)

[nd]

11.8 (4.9)

6 months

(PL)

APAP (AutoSet)

15

25.5 (14.7)

-4.4

-5.2

-13.51 to 3.11

nd

15

B

    

CPAP

14

17.1

(7)

0.8

     

Nolan 2007 [14]

17326544

15 (8)

[≥5)

12.3 (4)

2 months

(XO)

APAP

29

13.7 (7.8)

1.3

0.3

-3.29 to 3.89b

0.87

15

B

    

CPAP

29

13.7 (7.8)

1.0

     

Randerath 2001 [26]

11254519

35 (26)

[≥10]

11.1 (5.1)

1.5 months

(XO)

APAP

52

14 (11)

0

-1

-3.45 to 1.45

NS

12

B

    

CPAP

52

14 (11)

1.0

     

Resta 2004 [24]

15679008

47 (11)

[> 30]

13.9 (3.2)

1 month

(PL)

APAP

10

19.8 (10.9)

14

7.3

-2.35 to 16.95

nd

0

C

    

CPAP

10

22.8

(12.5)

6.7

     

Sériès 1997 [27]

9341056

44 (20)

[nd]

15.5 (4.5)

0.75 months

(PL)

APAPc

12

nd

ndd

-

-

NS

0

C

    

CPAP

12

nd

nd

     
    

APAPe

12

nd

ndd

-

-

NS

  
    

CPAP

12

nd

nd

     
  1. AHI: apnea-hypopnea index (events/hour); APAP: auto-titrating CPAP; CPAP; continuous positive airway pressure; ESS: Epworth Sleepiness Scale; nd: no data; NS: non-significant; PL: parallel design; XO: cross-over design. aEstimated from reported data. bEstimated from reported P value. cEstimated effective pressure. dDirections of changes not reported in the study. eMeasured effective pressure.